Cargando…
A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome
BACKGROUND: Alcohol withdrawal syndrome (AWS) is a distressing condition, generally controlled by benzodiazepines (BZD's). Baclofen, a gamma-aminobutyric acid-B (GABA(B)) agonist, has also shown promising results in controlling AWS. As there are few studies comparing the efficacy and tolerabili...
Autores principales: | Girish, K., Vikram Reddy, K., Pandit, Lakshmi V., Pundarikaksha, H.P., Vijendra, R., Vasundara, K., Manjunatha, R., Nagraj, Moulya, Shruthi, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chang Gung University
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138810/ https://www.ncbi.nlm.nih.gov/pubmed/27105601 http://dx.doi.org/10.1016/j.bj.2015.09.002 |
Ejemplares similares
-
Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome
por: Reddy, Vikram K., et al.
Publicado: (2014) -
Cost-effectiveness of the baclofen versus chlordiazepoxide in alcohol withdrawal syndrome
por: Tin, Sim Sai, et al.
Publicado: (2015) -
An imperative need to change pharmacology curriculum: A pilot survey
por: Vasundara, K., et al.
Publicado: (2010) -
Chlordiazepoxide-induced delirium in a patient undergoing alcohol withdrawal: a case report
por: Arabadjief, Melissa A., et al.
Publicado: (2022) -
Baclofen versus lorazepam for alcohol withdrawal
por: Garag, Sagar S., et al.
Publicado: (2019)